Investors

Spermatech AS is in the international research front of the male contraception field. Our strategy of targeting sperm specific proteins with high specificity and potentially no side effects opens for a unique male contraception pill. The annual market of today's contraceptives is currently at USD 7.5 billions and growing. A non-hormonal male contraception pill is excpected to take a substantial share of this market and expand it.

Spermatech AS is a privately held company financed by individual investors and the Research Council of Norway. The company seeks to create sustained shareholder value.

For further investor relations information, please contact:

Eirik Næss-Ulseth
Chief Executive Officer (CEO)
Mob: (+47) 92885883
E-mail: mail@spermatech.com